Study S000936

Effects of Liraglutide on Epicardial Fat Pro-Inflammatory Genes in Type 2 Diabetes and Coronary Artery Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT03260881
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: DOUBLE
Status: COMPLETED
Enrollment: 38
Start: 2018-09-01
Primary completion: 2024-09-05
Lead sponsor: University of Miami
Conditions: Type2 Diabetes; Coronary Artery Disease
Interventions: DRUG:Liraglutide Pen Injector [Victoza]; DRUG:matching liraglutide-placebo pre-filled pens
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

EAT Inflammation [Up to 12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0038344	449-P: Liraglutide Rapid Effects on Glucose and Adipose Tissue during and after CABG Gianluca Iacobellis, Diabetes	2024	Randomized trial	DOI	cites ClinicalTrials.gov:NCT03260881